Device of Tomorrow Capital
VC Fund
Anaheim, United States
Device of Tomorrow Capital is a VC fund in Anaheim focused on Health Care and Medical Device. Device of Tomorrow Capital
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Device of Tomorrow Capital invests in
Health CareMedical DeviceMedicalBiotechnologyManufacturing
Stages Device of Tomorrow Capital invests in
SeedSeries ASeries BPre-Seed
Countries Device of Tomorrow Capital invests in
United StatesUnited Kingdom
Investment Focus
Industry
- Health Care 9 (82%)
- Medical Device 6 (55%)
- Medical 5 (45%)
- Biotechnology 2 (18%)
- Manufacturing 2 (18%)
Stage
- Seed 5 (45%)
- Series A 3 (27%)
- Series B 2 (18%)
- Pre-Seed 1 (9%)
Country
- United States 10 (91%)
- United Kingdom 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
WearLinq
|
WearLinq is a provider of wearable health monitoring and diagnosis solutions. The company's device records a multi-lead ECG and transmits it in real-time with AI to detect typical irregular heart rhythms, including a normal heart rhythm, aFib, bradycardia, and tachycardia, allowing users to discover history and trends, set reminders, andconnect directly with physicians. | $14M / Series A / Dec 17, 2025 | |
Laplace Labs
|
A Game Changing AI native productivity operation system, more flexible and smarter | $500K / Pre-Seed / Oct 01, 2023 | |
Identical
|
Identical is a developer of personalized dental implants used to make tooth replacement more accessible and affordable for everyone. Its implants are drill-free and non-invasive and use the latest 3D technology that enables dentists to deliver personalized dental implants in a faster and safer way.It was founded in 2018 and is headquartered inWalnut Creek, California. | Seed / Jan 24, 2023 | |
Paloma Health
|
Paloma Health is the first online medical practice dedicated to transforming care for hypothyroidism. The HealthTech company offers a best-in-class experience for the 25 million Americans that struggle with the highly impactful chronic condition and are dissatisfied with the quality and convenience of their care.Paloma Health makes it easy toget expert, personalized treatment for hypothyroidism––all from the comfort of home. Delivered via telemedicine by expert, caring doctors and nutritionists, the company combines evidence-based treatment approaches with at-home lab testing to deliver the best care and experience available. | Series A / Jan 23, 2023 | |
Telesair
|
Telesair is a medical device company in stealth mode that is developing breakthrough respiratory care solutions to move patients from the hospital to home sooner. Their solutions elevate the existing standard of care by enhancing outcomes for patients and the health system. | $22M / Series A / Jan 10, 2023 | |
CARI Health
|
Cari Health develops remote medication monitors that allow clinicians to prescribe medications and receive real-time reporting on medication levels. Its monitors are wireless sensors that are worn on the patient's skin and continuously send data about medication levels to the cloud.The company was founded in 2015, incorporated in 2021 and isheadquartered in San Diego, California. | $2.3M / Seed / Jan 10, 2023 | |
Eximius Diagnostics
|
Eximius Diagnostics is a developer of non-invasive extracellular vesicles to detect early-stage liver cancer with nano-exosomes. Its non-invasive extracellular vesicles are based on in vitro diagnostics test and specialize in developing platform technologies for the purification and characterization of tumor-derived conditions from serum andplasma. | Seed / Jan 01, 2023 | |
Centerline Biomedical
|
Centerline Biomedical, Inc. was founded in November 2014 and is based on technology developed at the Cleveland Clinic. Centerline's mission is to develop advanced navigation systems that initially target interventional vascular procedures. | $33M / Series B / Jun 27, 2022 | |
Smartlens
|
Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | Seed / Dec 01, 2021 | |
Leo Cancer Care
|
Leo Cancer Care develops radiation therapy technologies that support cancer treatment in an upright patient position. The company designs integrated imaging, patient positioning, and treatment systems that are compatible with fixed radiation beam platforms used in photon and particle therapy. Its technology focuses on supporting the radiotherapyworkflow from patient simulation through treatment while enabling multiple radiation therapy modalities. Leo Cancer Care also collaborates with healthcare providers, research institutions, and industry partners to evaluate and advance the clinical use of upright radiotherapy systems. In addition to developing treatment technologies, the company works on expanding access to radiotherapy through solutions that aim to improve workflow efficiency and compatibility with existing treatment infrastructure. | $25.3M / Series B / Jul 20, 2021 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Climate VC Funds
33,091 investors
FAQ
What does Device of Tomorrow Capital invest in?
Device of Tomorrow Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Device of Tomorrow Capital last invest?
The most recent investment recorded for Device of Tomorrow Capital closed in Dec 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
